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INHIBITION OF INDUCIBLE 
NITRIC OXIDE SYNTHASE 
AMELIORATES RAT LUNG 
ALLOGRAFT REJECTION 
Recently, the inducible isoform of nitric oxide synthase has been shown to 
be an important immunomodulation molecule in allograft rejection. We 
have observed the production of nitric oxide during rejection and the effect 
of nitric oxide synthase inhibition on allograft rejection in a rat lung 
transplant model. Rat left lung allotransplants were performed in two 
strain combinations: brown Norway-to-F344 (major histocompatibility 
complex incompatible); and Lewis-tolF344 (minor loci incompatible) as 
severe and mild rejection models respectively. Syngeneic F344-to.F344 
transplants were performed as a negative control. Nitric oxide production 
during rejection was determined by measuring the recipient's erum 
nitrite/nitrate l vels as a stable end product of nitric oxide. The progression 
of rejection was evaluated radiographically and the grade of rejection was 
determined histologically. After operation, recipients of allotransplantation 
were randomly divided into two groups and received either aminoguanidine 
(200 mg/kg, intraperitoneal every 6 hours), a potent inducible nitric oxide 
synthase inhibitor, or normal saline treatment. The levels of serum nitrite 
and nitrate in recipients increased in the early phase of rejection in both 
allotransplant combinations. However, in the terminal phase of rejection, 
the serum nitrite/nitrate l vel decreased significantly compared with the 
peak level in the brown Norway-to-F344 recipients. The serum nitrite/ 
nitrate levels in the syngeneic transplant recipients were normal during the 
entire observation period. In aminoguanidine-treated animals, serum 
nitrite/nitrate levels remained normal in both allograft combinations. 
Significant suppression of rejection in aminoguanidine-treated recipients 
was observed histologically nd radiographically in comparison with un- 
treated recipients in the brown Norway-to-F344 combination. In the 
Lewis-to-F344 combination, aminoguanidine treatment significantly ame- 
liorated histologic rejection but did not affect radiologic appearance. We 
therefore conclude nitric oxide is produced uring early allograft rejection 
and may prove to be a marker and mediator of early rejection. The 
inhibition of inducible nitric oxide synthase results in significant reduction 
in rat lung allograft rejection. (J THORAC CARDIOVASC SURG 1995;110: 
1449-60) 
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L ung transplantation is now recognized as a ther- apeutic option for a variety of end-stage pulmo- 
nary diseases. Despite its increasing application, a
variety of problems continue to cause significant 
morbidity and mortality. Acute lung allograft rejec- 
tion develops to a variable degree in virtually all 
transplant recipients within the first 4 weeks after 
the operation) -4Although acute rejection is rarely 
fatal, it does increase morbidity. Furthermore, 
chronic rejection, the commonest cause of late 
mortality, is related to the frequency and cause of 
acute rejection episodes. Although much is known 
about the cellular alterations associated with al- 
lograft rejection, investigations directed at the mo- 
lecular mechanisms of the rejection process may 
foster development of more precise strategies of 
rejection prophylaxis. 
Nitric oxide (NO), a toxic atmospheric gas, is now 
known to exist in tissues as the smallest biologic 
product of mammalian cells. NO is synthesized from 
the amino acid L-arginine by a family of enzymes, 
the NO synthases. The constitutive isoform releases 
small quantities of NO for short periods in response 
to receptor or physical stimulations. NO derived 
from the constitutive isoform of NO synthase acts as 
a physiologic regulator by relaxing vascular smooth 
muscle s or by functioning as a neurotransmitter. 6 
The inducible isoform of NO synthase can be ex- 
pressed in several cell types, including activated 
macrophages and endothelial cells. Once expressed, 
the inducible isoform synthesizes larger quantities of 
NO for longer time periods. 
Recently, inducible NO has been found to play an 
important role in immunologic cellular interac- 
tions. 7-9 Increased production of NO has been dem- 
onstrated uring acute allograft rejection, 1°-13 which 
suggests that NO may play an important role in the 
in vivo response to allogeneic tissue. The role of NO 
in allograft rejection is still unclear; however, in 
vitro experiments demonstrated a possible role in 
promoting lymphocyte proliferation. 14~6 Worrall 
and associates 13 have recently demonstrated that 
NO synthase is induced during cardiac allograft 
rejection and that selective inhibition of the induc- 
ible isoform significantly attenuated cardiac al- 
lograft rejection in the rat. 
The present study was undertaken to determine if
NO was produced during lung allograft rejection 
and to determine if selective inhibition of the induc- 
ible isoform of NO synthase with aminoguanidine, a 
selective inhibitor of the inducible isoform, 17' 18 
would ameliorate the rejection process. 
Materials and methods 
Animals. Inbred, male, specific-pathogen-flee brown 
Norway (BN: RTI"), Lewis (LEW: RTll), and F344 
(RT1 lvl) rats, weighing 250 to 300 gin, were purchased 
from Harlan Sprague-Dawley (Indianapolis, Ind.). The 
animals were given humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the National Academy of Sciences and pub- 
lished by the National Institutes of Health (NIH Publica- 
tion No. 86-23, revised 1985). 
Transplantation. Lung allotransplantation was per- 
formed in an RT1 (major histocompatibility complex) 
incompatible donor-recipient combination (BN donor 
into F344 recipients), as well as in a combination i com- 
patible for minor loci (LEW to F346), to severe and mild 
rejection models, respectively. Additionally, syngeneic 
transplants were performed in an F344 to F344 combina- 
tion. F344 rats were used as recipients in all groups. The 
orthotopic left lung transplantation procedure used in this 
study was a modification of the "cuff" technique) 9 In 
brief, the donor rats were anesthetized with intraperito- 
neal administration of pentobarbital (20 mg/kg) after 
intramuscular injection of atropine (0.25 mg/kg) and 
ketamine (25 mg/kg). After intravenous administration f 
heparin (1000 U/kg) and median sternotomy with the rat 
mechanically ventilated with room air, both lungs were 
flushed with cold (1 ° C) low potassium dextran-l% glu- 
cose (LPDG) solution at 20 cm H20 pressure. The 
heart-lung block was excised with the lungs inflated at end 
tidal volume and immersed in cold (1 ° C) low potassium 
dextran-1% glucose solution until implantation. Recipi- 
ent animals were intubated and anesthesia was main- 
tained by mechanical ventilation with halothane and oxy- 
gen by the use of a small-animal ventilator (Harvard 
Rodent Ventilator, South Natick, Mass.). After left pneu- 
monectomy was performed, the pulmonary artery and 
vein were anastomosed with the aid of polyethylene cuffs 
with internal diameters of 1.65 mm and 2.20 mm, respec- 
tively, and the left main bronchus was anastomosed with 
8-0 Prolene running suture (Ethicon, Inc., Somerville, 
N.J.). 
After left lung transplantation i  rats, radiographic 
assessment of the graft can be obscured by the right lung. 
Therefore, a postcaval lobectomy on the recipient right 
lung was performed immediately after implantation i  
each recipient so as to facilitate radiographic assessment 
of the left lung allograft. After the chest wall was closed, 
a silicone tube was placed intraperitoneally, tunneled 
subcutaneously, and brought out posteriorly behind the 
animal's head to provide access for regular intraperitoneal 
drug administration. Animals were given supplemental 
oxygen for 24 hours after the operation. No immunosup- 
pressive medication was used in this study. 
Rats having acute allograft dysfunction as evidenced by 
abnormalities on the chest roentgenogram i mediately 
after implantation were excluded from the analysis on the 
basis of technical failure. 
Experimental groups. The total number of transplants 
was 17 in the BN-to-F344 group, 16 in the LEW-to-F344 
group, and 7 in the syngeneic group. Allograft recipients 
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Table I. Expetqrnental groups 
Strain combination Aminoguanidine treatment Graft ischemic time (rain) Day of planned death n 
BN to F344 Yes 109.00 _+ 7.60 1 7 9 
No 108.78 _+ 5.24 f NS 8 
LEW to F344 Yes 105.88 ± 5.82 / 14 8 
No 108.00 _+ 4.81 f NS 8 
F344 to F344 No 109.43 ± 7.04 / 7 
Aminoguanidine tr atment was performed by injecting a 200 mg/kg dose of aminoguanidine hemisulfate intraperitoneally through the implanted catheter 
every 6 hours until the rat was put to death. The first administration was performed 6 hours after implantation. Control group in each combination a d 
syngeneic group (F344 to F344) received same amount of normal saline solution i  the same manner. NS, Not significant. 
from each strain combination were randomized into two 
groups and were treated with either aminoguanidine or
normal saline solution (Table I). The aminoguanidine- 
treated group received 1.5 ml of normal saline solution 
containing a 200 mg/kg concentration of aminoguanidine 
hemisulfate salt (Sigma Chemical Company, St. Louis, 
Mo.) with a 0.5 mg/kg dose of gentamicin (aminoguani- 
dine-treated group) intraperitoneally through the im- 
planted catheter every 6 hours until the rat was put to 
death. The control group received 1.5 ml of normal saline 
solution containing only a 0.5 mg/kg concentration of 
gentamicin (untreated group) intraperitoneally every 6 
hours in a similar fashion. All recipients of syngeneic 
transplants (n = 7) received normal saline solution with a 
0.5 mg/kg dose of gentamicin i traperitoneally in the same 
manner. The first administration i all groups was per- 
formed 6 hours after implantation. 
Serum nitrite~nitrate assay. Recipient NO production in 
each group was determined by measuring serum nitrite/ 
nitrate levels, which are stable end products of NO 
metabolism,lO, 2Oat serial time points after transplanta- 
tion. Blood samples for this assay were obtained from the 
tail artery on  days 4 and 7 in the recipients of BN 
allografts and on days 7, 11, and 14 in the LEW allograft 
recipients. Blood samples for this assay were taken from 
the syngeneic group on days 4, 7, and 14. Additionally, the 
blood samples from three normal F344 rats served as 
controls. In this study, serum nitrite/nitrate l vels were 
determined by the recently described fluorometric assay 
reported by Misko and colleagues. 21 In brief, serum 
samples were first filtered through a 10,000 molecular 
weight (Mw) cutoff filter to remove the hemoglobin 
resulting from cell lysis. The serum nitrate was converted 
to nitrite by the action of nitrate reductase by incubating 
with 40 reduced nicotinamide adenine dinucleotide phos- 
phate (NADPH), 40/xmol/L (to initiate the reaction), and 
14 mU of nitrate reductase (Sigma) in a final volume of 50 
tzl of Tris buffer (20 mmol/L), pH 7.6. The reaction was 
terminated after 5 minutes at 20 ° C by dilution with 50/xl 
of water fol!owed by the addition of 2,3-diaminonaphtha- 
lene for determination of nitrite. 2,3-Diaminophthalene 
reacts with nitrite under acidic conditions to form 1-(H)- 
naphthotriazole, a fluorescent product. Formation of 
1-(H)-naph~hotriazole was measured with a Pandex fluo- 
rescent pla~e reader (IDEXX Laboratories Inc., West- 
brook, Maine ) with excitation at 365 nm and emission 
read at 450 nm with a gain setting of 100%. Nitrite levels 
in the sampies were then calculated by first subtracting the 
value of the enzyme blank (i.e., nitrate reductase plus 
NADPH) from the experimental value and then calculat- 
ing the value using a standard curve for nitrite to which 
NADPH has been added. Plasma volumes of 10/xl or less 
routinely give a linear response in this assay. 
Radiographic analysis. Transplanted lungs were as- 
sessed radiographically each day in the recipients of BN 
allografts and every other day in animals with LEW 
allografts during spontaneous ventilation with halothane 
inhalation for sedation. The first examination was per- 
formed on day 1 after transplantation. Anteroposterior 
chest roentgenograms were taken with the rat in a slightly 
left anterior oblique position so as to provide maximum 
exposure of the transplanted left lung. Results of each 
chest x-ray film were graded according to a previously 
published aeration score 22 by a blinded observer (score 
0 = opaque lung up to score 6 = normal-appearing lung). 
Recipients of syngeneic transplants did not undergo ra- 
diographic assessment, because the purpose of this group 
was to evaluate the production of NO in association with 
surgical stress and ischemia-reperfusion njury. 
tIistologic studies. Recipients of BN allografts were 
put to death on day 7, by which time complete graft 
rejection would be expected histologically and radio- 
graphically in this severely mismatched combination (Shi- 
raishi and associates, unpblished ata). Our preliminary 
study in LEW allograft recipients demonstrated that the 
histologic peak of rejection was on day 1423; however, 
complete rejection in this combination is less clearly 
defined, and occasionally spontaneous recovery occurs 3 
24 weeks after transplantation. Therefore, those recipients 
were put to death on day 14. At their death, 10% buffered 
formaldehyde solution was infused into the trachea at a 
hydrostatic pressure of 20 cm H20. The heart and lungs 
were then removed en bloc from the thoracic cage. 
Allografts were divided in a coronal plane through the 
main bronchus o as to produce two equal sections and 
maximal ongitudinal bronchial ength. Paraffin sections 
were stained with hematoxylin and eosin for examination 
with a light microscope. Acute rejection was evaluated 
histologically and assigned a rejection score based on the 
clinical international working formulation: IWF grade A0, 
no significant abnormality; grade A1, scattered infrequent 
perivascular mononuclear infiltration; grade A2, frequent 
perivascular mononuclear infiltration; grade A3, exten- 
sion of mononuclear infiltration into alveolar septum/ 
spaces; and grade A4, diffuse perivascular, interstitial, and 
air space infiltration of mononuclear cellsY In addition, 
allografts were also evaluated according to the scoring 
system devised by Prop and coworkers 26 for rat lung 
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Fig. 1. Change of serum nitrite/nitrate l vels in the F344 
recipients of BN and LEW allografts. A, BN-to-F344: The 
levels of serum nitrite/nitrate in aminoguanidine-treated 
(closed circle, n = 4) or untreated (open circle, n = 4) 
recipients of BN allografts and recipients of F344 syngeneic 
grafts: (open cross, n = 4) were determined on the postop- 
erative days indicated. B, LEW-to-F344: The levels of serum 
nitrite/nitrate in aminoguanidine-treated (closed circle, n = 
6), untreated (open circle, n = 6) recipients of LEW al- 
lografts and recipients of syngeneic graft (open cross, n = 4) 
were determined on the postoperative days indicated. Each 
point represents he mean +_ standard eviation. The symbol 
* indicates the mean _+ SEM normal level in F344 rats (n = 
3). The symbol t indicates that values for untreated recipi- 
ents are significantly different from those of treated and 
syngeneic recipients, tP < 0.05; t?p < 0.01. 
allograft rejection: grade 0--latent phase, no signs of 
rejection; grade 1--vascular phase; perivascular nd bron- 
chus-associated lymphoid tissue infiltration; grade 2--al- 
veolar phase, alveolar infiltration; grade 3--destruction 
phase, graft destruction. Both histologic assessments were 
performed by a blinded pathologist (J.H.R.). This histo- 
logic assessment was not performed on the syngeneic 
grafts. 
Statistical analysis. The data were expressed as 
mean -- standard eviation. Intergroup comparisons of 
radiographic and histologic parameters were analyzed by 
the Mann-Whitney U test. Serum nitrite/nitrate l vels 
were compared by two-way analysis of variance. Multiple 
comparisons were made using the Tukey highest signifi- 
cant difference post-hoc test. Differences were considered 
significant if the p value was less than 0.05. 
Results 
All animals survived the transplant procedure. 
One BN allograft recipient reated with aminogua- 
nidine died of empyema on postoperative day 4 and 
was excluded from subsequent analysis. Early al- 
lograft function was satisfactory in all animals; 
therefore no animals were excluded on the basis of 
radiographic score. Total all0graft ischemic time did 
not differ significantly between aminoguanidine- 
treated and untreated recipients of both the BN and 
LEW allograft groups (Table I). 
Serum nitrite/nitrate level 
F344-to-F344. Serum nitrite/nitrate l vels in the 
normal F344 rats was 8.0 + 1.0 t~mol/L (n = 3). The 
serum nitrite/nitrate l vels of syngeneic recipients 
did not differ from normal values (Fig. 1). 
BN-to-F344. In the BN allograft group, the serum 
nitrite/nitrate l vels of the untreated recipients were 
significantly higher than those of the aminoguani- 
dine-treated recipients or syngeneic recipients on 
days 4 and 7. The value on day 4 was significantly 
higher than on day 7 in the untreated recipients. 
Normal values were found in the aminoguanidine- 
treated recipients at each time point (Fig. 1, A). 
LEW-to-F344.  In the LEW allograft group, the 
serum nitrite/nitrate l vels of the untreated recipi- 
ents were significantly higher than those of the 
aminoguanidine-treated r cipients on days 7, 11, 
and 14. Values for aminoguanidine-treated r cipi- 
ents were within normal limits at each time point 
(Fig. 1, B). 
Radiographic findings 
BN-to-F344. All recipients of BN allografts 
showed excellent aeration of the transplanted left 
lung during the first 4 days after operation. From 
day 5 until the rats were put to death at day 7, there 
was a progressive decrease in aeration score in the 
untreated group, and on day 7 all eight untreated 
recipients had a completely opaque chest x-ray film. 
Aminoguanidine-treated r cipients had less opacifi- 
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cation of the lung graft between days 5 and 7. A 
significant difference was present at days 6 and 7 
between untreated and treated recipients (1.75 _+ 
0.87 versus 4.08 + 1.39 on day 6, p = 0.017; 0.9 + 
0.74 versus 4.17 + 1.40 on day 7,p = 0.006) (Fig. 2, 
A and Fig. 3). 
LEW-to.F344. All recipients of LEW allografts 
had clear chest x-ray films until being put to death. 
There were no significant differences between 
treated and untreated groups at each time point 
through tlleir planned deaths (Fig. 2, B). 
Pathologic findings 
BN-to-F344. Macroscopic inspection under me- 
chanical ventilation at the time of sacrifice revealed 
that all eight untreated BN allograft recipients 
showed significant heparinization, scattered hemor- 
rhage, massive atelectasis, and complete consolida- 
tion without aeration whereas all nine allografts in 
the treated group were well ventilated. In contrast, 
the grafted lungs in aminoguanidine-treated r cipi- 
ents appeared similar to the contralateral native 
lungs (Fig. 4). The radiographic findings of less 
rejection in the aminoguanidine-treated group were 
confirmed! histologically (Fig. 5). Significant im- 
provements in the histologic stage of rejection be- 
tween untreated and treated groups were found by 
means of both the clinical and the Prop scoring 
systems ini the recipients of BN allografts (3.75 __ 
0.54 versus 2.61 _+ 0.22 in IWF grade, p = 0.0015; 
2.63 _+ 0.74 versus 1.33 _+ 0.35 in the Prop score, p = 
0.0042) (Fig. 6, A). 
LEW-to:F344. All recipients of LEW allografts 
had well-ventilated lungs. According to the IWF 
grading system, aminoguanidine-treated recipients 
had less rejection than the untreated group (2.5 _+ 0 
versus 2.251 _+ 0.27, in untreated and treated groups, 
respectively, p = 0.025). There was no significant 
difference, however, when the groups were com- 
pared by means of Prop's scoring system (Figs. 6, B 
and 7). 
Discussion 
Recently NO has been found to play a fundamen- 
tal role in host immune defense, s Activated macro- 
phages can be induced to express the inducible 
isoform of NO synthase, thereby oxidatively metab- 
olizing the amino acid L-arginine to produce NO, 
citrulline, nitrite, and nitrase. This pathway was 
found to be enhanced in the presence of lipopoly- 
saccharide land the cytokines interleukin-2, interfer- 
on-y, and iumor necrosis factor-aS NO produced 
by macrop~lages has been demonstrated to respond 
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Fig. 2. A and B, Change of chest x-ray findings in the 
F344 recipients of BN and LEW allografts Aeration score 
indicates 0 for opaque to 6 for normal-appearing lung. 
Closed circle and open circle demonstrate aminoguanidine- 
treated and untreated recipients, respectively. Each point 
represents he mean -+ standard eviation. The symbol ? 
indicates values that are significantly different in inter- 
group comparison, tp < 0.05; ??p < 0.01. 
as a nonspecific defense mechanism against a variety 
of pathogens 2s-31 and tumor cells. 3244 The biochem- 
ical basis of this cytostatic/cytotoxic function in- 
duced by NO is thought to be a result of nitrosyla- 
tion and inhibition of key enzymes involved in the 
respiratory cycle and the synthesis of deoxyribonu- 
cleic acid in the target cells, s' 35, 36 
The production of NO during allograft rejection 
has been demonstrated in several experimental 
1454 Shiraishi et al. 
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Untreated Treated 
Fig. 3. Chest x-ray films Of F344 recipients of BN allografts. Representative chest x-ray (anteroposterior 
view) photographs ofaminoguanidine-untreated (left) and treated (right) recipients of BN allografts 7 days 
after transplantation. Black arrows indicate transplanted left lungs. Transplanted lungs of untreated 
recipients were completely opaque (aeration score = 0), whereas treated animals demonstrated only 
minimal changes in infiltration (aeration score = 5). 
Untreated Treated 
Fig. 4. Gross view of BN lung allografts on day 7 after transplantation. Gross examination of the 
transplanted left lung (arrow) showed significant signs of heparinization with massive atelectasis in the 
untreated recipient (left), whereas the aminoguanidine-treated recipient appeared similar to the native 
contralateral lung (right). 
models. Increased NO production, as measured by 
elevated serum nitrite/nitrate l vels, was found in 
the recipients of rejecting rat heart, liver, small 
bowel, and bone marrow allografts] °'13 Similarly, 
allosensitized rat-sponge-matrix allograft-infiltrating 
cells were found to produce higher quantities of NO 
than did cells infiltrating syngeneic grafts in murine 
and rat models. 2v' 37-40 Direct evidence of NO in 
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Fig. 5. Representative photomicrographs of BN allografts o F344 recipients at day 7 after transplantation 
(×400). a, Aminoguanidine-untreated recipient: severe rejection with confluent, destructive infiltrates 
(IWF grade 4; Prop score 3). b, Aminoguanidine-treated recipient: m ld toweak rejection; perivascular 
infiltrates are present without extension into alveoli (IWF grade 2 to 3, Prop score 1). 
cardiac allqgrafts has been obtained by electron 
paramagnetic resonance spectroscopy, which de- 
tected the Signals for nitrosylferrohemoglobin and
nonheme iron-dinitrosyl complexes in the allograft 
tissue.12, 13 The increased levels of serum nitrite and 
nitrate in a!lograft recipients can be suppressed by 
treatment with the immunosuppressive drugs FK 
50638 and gyclosporine A. 1° Moreover, when the 
immunosuppressive th rapy was terminated and his- 
tologic evidence of recurrent rejection was found, 
elevated serum nitrite/nitrate l vels were detected. 
These data seem to suggest that NO is produced 
in association with rejection and may have some 
important role in the rejection process. However, 
the mechanism of NO production and the role of 
NO in allograft rejection is unclear. Several reports 
demonstrate NO mediated in vitro T-lymphocyte 
suppression. NO produced by concanavalin A-stim- 
ulated rat splenocytes is associated with a profound 
suppression of lymphocyte proliferation. Further- 
more, inhibition of NO production with L-N-nitroso- 
N-methylalanine markedly promotes this mitogenic 
1456 Shiraishi et al. 
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Fig. 6. Rejection scores of BN and LEW allografts when 
the rats were killed. BN lungs 7 days after transplantation 
to F344 recipients (A) and LEW lungs 14 days after 
transplantation to F344 recipients (B). Black bars and 
white bars indicate the allografts of aminoguanidine- 
treated and untreated recipients, respectively. Rejection 
was evaluated histologically on the basis of perivascular 
infiltration according to the IWF (IWF grade A0, no 
significant abnormality; grade A1, scattered infrequent 
perivascular mononuclear infiltration; grade A2, frequent 
perivascular mononuclear infiltration; grade A3, exten- 
sion of mononuclear infiltration into alveolar septum/ 
spaces; grade A4, diffuse perivascular, interstitial, and air 
space infiltration of mononuclear cells). Allografts were 
also evaluated according to the Prop scoring system for rat 
lung allograft rejection (grade 0--1atent phase: no signs of 
rejection; grade 1--vascular phase: perivascular nd bron- 
chus-associated lymphoid tissue infiltration; grade 2--al- 
veolar phase: alveolar infiltration; grade 3--destruction 
phase: graft destruction). All values are expressed as 
mean +- standard eviation of the mean. The symbol ? 
indicates values that are significantly different in inter- 
group comparison. ?p < 0.05; ??p < 0.01. 
response to concanavalin A. 41 NO has also been 
shown to down-regulate certain macrophage func- 
tions, including superoxide production, phagocyto- 
sis, and protein synthesis. 42' 43 Langrehr,20, 27, 39 
Hoffman, 4° and their associates, using a sponge 
matrix allotransplant model, demonstrated that NO 
production in the rat and mouse splenocyte mixed- 
lymphocyte reaction promoted a profound inhibi- 
tory effect on cytotoxic T-lymphocyte induction. 
These findings eem to suggest a suppressive role for 
NO in alloreactivity. 
Other studies, however, suggest an immunostimu- 
lating capacity of NO. Efron and colleagues TM used 
phytohemagglutinin-stimulated human mononu- 
clear cell culture to describe the ability of NO to 
promote deoxyribonucleic acid synthesis and 
thereby enhance lymphocyte proliferation. These 
data appear at first glance to be paradoxic and 
contrary to the reports that demonstrate he inhib- 
itory effect of NO on lymphocyte proliferation. 
More recently, a similar promotive ffect of NO on 
lymphocyte proliferation was demonstrated in a 
murine splenocyte culture model. 15 In addition, 
Sugiyama nd associates 16noted that inhibition of 
NO synthase by aminoguanidine inhibits cell prolif- 
eration without cell death by prolonging the M- 
phase of the cell cycle in rat liver and human tumor 
cell lines. Considering these discordant observations 
on the immunoregulatory roles of NO, it is likely 
that NO plays multiple roles in allograft rejection. 
For the particular effect of NO on transplanted 
allograft rejection to be elucidated, further experi- 
ments using vascularized organ transplant models 
seem necessary because previous tudies have been 
performed with in vitro cell culture models or 
nonvascularized "sponge matrix" transplant models. 
Recently, Worrall and associates 13 have demon- 
strated that the inducible isoforme of NO synthase is
expressed in the inflammatory cells infiltrating car- 
diac allografts and that inhibition of the inducible 
isoform prolonged cardiac allograft survival and 
improved graft function. This suggests that the net 
role of NO is to promote organ rejection. 
In the present study, we have demonstrated that NO 
is produced uring lung allograft rejection, and selec- 
tive inhibition of the inducible isoforme of NO syn- 
thase with aminoguanidine significantly attenuated the 
rejection process. NO production was demonstrated 
by elevated serum nitrite/nitrate l vels in untreated 
F344 recipients of both "weak mismatched" LEW and 
"strong mismatched" BN lung allografts. In recipients 
of both LEW and BN allografts, the levels of serum 
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Fig. 7. Representative photomicrographs of LEW allografts to F344 recipients at day 14 after transplan- 
tation (× 400). a, LEW atlograft from aminoguanidine untreated recipient: mild tomoderate r jection with 
perivascular lymphoid cuffs and minimal extension to alveoli, b, Treated recipient: slight rejection 
compared with untreated recipient. 
nitrite and nitrate started to increase during the early 
phases of rejection. Indeed, in the recipients of LEW 
allografts, el.evated levels of serum ifitrite and nitrate 
were detected on day 7. Yet, we 23 have previously 
shown that at day 7 this same untreated LEW-to-F344 
combinatior~ demonstrated a low-grade histologic re- 
jection (IWF grade = 2.06 _+ 0.18). In the recipients of 
rapidly rejecting BN allografts, increased serum nitrite/ 
nitrate levels were detected on day 4 but were signifi- 
cantly decreased by day 7, when complete histologic 
rejection had occurred. We were not able to observe a
similar decrease in serum nitrite/nitrate l vel in the 
"weak mismatched" LEW allograft recipients. These 
data suggest that serum nitrite/nitrate levels may serve 
as an early marker of rejection. With complete rejec- 
tion, however, the destruction and thrombosis of mi- 
crovasculature in the allograft may result in decreased 
release of NO from the rejecting organ. Aminoguani- 
dine treatment normalized the serum nitrite/nitrate 
levels in both allotransplant strain combinations 
throughout the time-course of rejection. 
Graft survival studies are generally not performed 
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in the rat lung transplantation model because of the 
complexity of assessing function of the allograft. 
Consequently, radiographic and histologic analysis 
have served as the standard parameters in measur- 
ing the severity of rejection. Both treated and un- 
treated recipients of "strong mismatched" BN al- 
lografts howed excellent radiographic findings until 
day 4 after transplantation. However, after days 5 to 
7, the aeration score progressively decreased in the 
untreated group whereas the treated group showed 
only minimal decrease. These observations corre- 
lated well with the histologic rejection scores. Sig- 
nificant differences in rejection scores were ob- 
served with both IWF grade and Prop scoring 
systems. In the group of "weak mismatched" LEW 
allograft recipients, there was no difference in the 
x-ray findings between treated and untreated 
groups. However, the histologic IWF grade was 
slightly but significantly suppressed in treated recip- 
ients. 
Although it may be possible that aminoguanidine 
acted via a different mechanism and the serum 
nitrite/nitrate l vels were merely reflective of the 
degree of rejection, we believe that it was the 
inhibition of the inducible isoforme of NO synthase 
that by aminoguanidine r sulted in the lower level of 
NO. We may hypothesize that the lower graft level 
of NO resulted in a less severe alloimmune response 
and led to a delay in rejection in those grafts. 
Additionally, considering the chemical capacity of 
NO as a free radical, there is another possible 
mechanism for the promotive ffect of NO on the 
rejection process. It has been demonstrated that 
nonspecific injury, such as viral infection or isch- 
emia-reperfusion i jury, might predispose the al- 
lograft to subsequent rejection through up-regula- 
tion of class II major histocompatibility complex 
antigens 44 or increased local production of cytokines 
in the allograft 45 that closely relate to the rejection 
process. Therefore we hypothesize that NO injures 
allografts and results in increased alloantigenicity. 
We conclude that aminoguanidine suppressed the 
production of NO associated with rejection and 
ameliorated rat lung rejection as a net effect. The 
role of NO in the rejection process remains unclear. 
Further immunologic or molecular biologic investi- 
gation seems to be necessary to elucidate the mech- 
anism. 
We thank Richard B. Schuessler, PhD, for his expertise 
in the statistical evaluation, Dawn G. Schuessler for 
preparation of manuscript, and Donna M. Marquart for 
technical support. 
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Discussion 
Dr. Robert J. Keenan (Pittsburgh, Pa.). This is a well- 
designed study that builds on previous work at Washing- 
ton University on the role of NO synthase inhibition on 
modulation of cardiac allograft rejection. Dr. Shiraishi's 
research provides further evidence of the central role of 
NO in inflammatory processes. 
The authors present data suggesting that NO produc- 
tion, as measured by serum nitrite/nitrate l vels, is accel- 
erated during early allograft rejection and that inhibition 
of inducible NO synthase by aminoguanidine ameliorates 
this activity and suppresses the rejection response. The 
evidence for this effect is based on histologic and radio- 
graphic criteria. In the written discussion the authors 
suggest that NO directly damages the allograft in the early 
posttransplantation period and that this damage leads to 
increased antigen expression and an enhanced allograft 
response. The paper does not present much data to 
support hat hypothesis. 
I have three questions. First, why did you wait until 
postoperative day 4 to assess NO production inasmuch as 
the peak of NO activity may well have been earlier in the 
process and you may have been catching this activity on 
the down slope? 
Second, aminoguanidine, although a much more potent 
inhibitor of inducible NO synthase, does in fact have some 
activity against constitutive NO synthase activity. Did you 
look at alternative methods for detection of inducible NO 
synthase such as Northern Blot analysis or, more partic- 
ularly, immunostaining to confirm that the effect you saw 
was truly due to inducible NO synthase inhibition? 
Third, have you done any characterization f the cellu- 
lar infiltrate and its time course over the rejection process 
to establish whether inducible NO synthase inhibition 
interferes with entry of circulating allograft cells into the 
graft or with inhibition of lymphocyte proliferation once 
those cells have entered the lung? 
Dr. Shiraishi. Thank you, Dr. Keenan. You asked why 
we did not measure nitrite and the nitrate in the early 
period. The first paper concerning the increased produc- 
tion of NO was presented by Dr. Rambla and the group at 
Pittsburgh University. Using a wholly allogenic rat heart 
and liver and a small interesting transplant model, they 
demonstrated increased nitrate and nitrite levels in serum 
in the process of rejection. They started their assessments 
on day 3, and there was a very small but significant 
difference. Because this difference became bigger associ- 
ated with rejection, we decided to start my assessment 
from day 4. 
This question includes the possibility that NO is pro- 
duced in association with ischemic-reperfusion njury, so 
we probably could get more useful and additional infor- 
mation about NO metabolism, not nly as a marker of 
ischemic-reperfusion njury, but also as an earlier marker 
of rejection. 
The second question concerned whether aminoguani- 
dine is an inducible NO synthase inhibitor. Unfortunately, 
we did not do any immunohistochemical staining for this 
study, so we have no clear answer. 
The third question concerns the mechanism of NO in 
the rejection process. We have two hypotheses for the role 
of NO in the rejection process. One is its cytotoxic effect. 
NO was first demonstrated to be more cytotoxic against 
tumor cell line or pathogen or transplanted islet cells. 
Such injury may increase or up-regulate he autogenicity 
of transplanted organs. It may cause a high potential of 
rejection. The other possibility is its lymphoproliferative 
effects. We believe such potential will increase a tendency 
for rejection, but in this particular study we did not do any 
mechanical study, so we have no answer. 
